CDK5 and neoplasm: We further revealed that the increased sensitivity of tumor cells to oxaliplatin induced by CDK5 was restored by E2F1 knockdown (Additional file 10: Figure S6D), suggesting that CDK5-induced chemosensitivity is dependent on E2F1.